CIK 0001398733 · Non-accelerated filer<br>Smaller reporting company
Aquestive Therapeutics, Inc.
Sign in to watch- Ticker
- AQST
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 208623253
- Phone
- 908-941-1900
- Business address
- 184 LIBERTY CORNER ROAD, SUITE 305, WARREN, NJ
- Former names
- MonoSol Rx, Inc.
- Open-market buys, last 90 days
- $99,331
- in 1 filing
- Open-market sales, last 90 days
- $378,930
- in 4 filings, $379K under 10b5-1 plans
Net −$279,599. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-07 | BRAENDER LORI J SVP, General Counsel | Grant or award · Non-Qualified Stock Option (right to buy) | +67,500 | 67,500 | ||
| 2024-03-07 | TOTH A ERNEST JR SVP, Chief Financial Officer | Grant or award | +120,000 | 260,000 | ||
| 2024-03-07 | TOTH A ERNEST JR SVP, Chief Financial Officer | Grant or award · Non-Qualified Stock Option (right to buy) | +60,000 | 60,000 | ||
| 2024-03-07 | Schobel Alexander Mark Chief Innovation/Tech Officer | Grant or award | +82,500 | 1,065,371 | ||
| 2024-03-07 | Schobel Alexander Mark Chief Innovation/Tech Officer | Grant or award · Non-Qualified Stock Option (right to buy) | +41,250 | 41,250 | ||
| 2024-03-07 | Kraus Carl N Chief Medical Officer | Grant or award | +112,500 | 262,500 | ||
| 2024-03-07 | Kraus Carl N Chief Medical Officer | Grant or award · Non-Qualified Stock Option (right to buy) | +56,250 | 56,250 | ||
| 2024-03-07 | Barber Daniel President and CEO | Grant or award | +242,600 | 883,302 | ||
| 2024-03-07 | Barber Daniel President and CEO | Grant or award · Non-Qualified Stock Option (right to buy) | +363,900 | 363,900 | ||
| 2024-03-07 | Jung Cassie SVP, Operations | Grant or award | +101,250 | 247,186 | ||
| 2024-03-07 | Jung Cassie SVP, Operations | Grant or award · Non-Qualified Stock Option (right to buy) | +50,625 | 50,625 | ||
| 2024-03-07 | Boyd Peter E. See Remark | Grant or award | +86,250 | 245,998 | ||
| 2024-03-07 | Boyd Peter E. See Remark | Grant or award · Non-Qualified Stock Option (right to buy) | +43,125 | 43,125 | ||
| 2024-03-07 | Wargacki Stephen SVP, Research & Development | Grant or award | +112,500 | 270,919 | ||
| 2024-03-07 | Wargacki Stephen SVP, Research & Development | Grant or award · Non-Qualified Stock Option (right to buy) | +56,250 | 56,250 | ||
| 2023-08-09 | BRAENDER LORI J SVP, General Counsel | Grant or award · Performance Stock Units | +75,000 | 75,000 | ||
| 2023-08-09 | Barber Daniel President and CEO | Grant or award · Performance Stock Units | +223,500 | 223,500 | ||
| 2023-08-09 | Boyd Peter E. See Remark | Grant or award · Performance Stock Units | +50,000 | 50,000 | ||
| 2023-08-09 | Wargacki Stephen SVP, Research & Development | Grant or award · Performance Stock Units | +67,500 | 67,500 | ||
| 2023-08-09 | TOTH A ERNEST JR SVP, Chief Financial Officer | Grant or award · Performance Stock Units | +70,000 | 70,000 |
Page 9 of 24 · 462 trades